Status:
COMPLETED
Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
Lead Sponsor:
Lexicon Pharmaceuticals
Conditions:
Primary Open-angle Glaucoma
Ocular Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
This Phase 1/2a study is intended to assess the safety, tolerability, and effects on intraocular pressure of two dose levels and two dose frequencies of LX7101 when administered topically in the eyes ...
Eligibility Criteria
Inclusion
- Adults ≥18 years of age
- Documented diagnosis of POAG or OHT, in both eyes
- Willing and able to provide written informed consent
Exclusion
- History of any form of glaucoma in either eye, other than POAG
- Subjects who are unwilling or unable to discontinue contact lens wear prior to and during study
- History of ocular trauma in either eye \<6 months prior to Screening
- History of ocular infection or ocular inflammation in either eye \<3 months prior to Screening
- History of chronic or recurrent severe inflammatory eye disease, any severe ocular pathology, or clinically relevant or progressive retinal diseases in either eye
- Clinically relevant, severe central visual field loss, or documented significant progression of a visual field defect within 6 months prior to Screening in either eye
- Use of any ocular hypertensive medications (if applicable), in either eye, during the washout period and for the duration of the study
- Use of any glucocorticoid medications \<2 weeks prior to Screening and throughout the duration of the study
- Use of any medication or substance on a chronic basis which has not been taken at a stable dose for at least 30 days prior to Screening
- Use of any nondiagnostic, topical, ophthalmic preparations, in either eye, other than artificial tears
- The presence of any concurrent condition or clinically significant laboratory findings at Screening that may interfere with any aspect of safety, study conduct, or interpretation of results
- Women who are pregnant or breast feeding
- Inability or difficulty instilling eye drops
Key Trial Info
Start Date :
March 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2012
Estimated Enrollment :
63 Patients enrolled
Trial Details
Trial ID
NCT01528111
Start Date
March 1 2012
End Date
June 1 2012
Last Update
September 14 2015
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Lexicon Investigational Site
Morrow, Georgia, United States, 30260
2
Lexicon Investigational Site
Memphis, Tennessee, United States, 38119
3
Lexicon Investigational Site
Austin, Texas, United States, 78731
4
Lexicon Investigational Site
Houston, Texas, United States, 77025